Thursday, June 26, 2025

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Related stories

Rubrik to Acquire Predibase for Agentic AI Expansion

Rubrik, Inc. has entered into an agreement to acquire...

AlphaSense Launches EU Data Region for Market Intelligence

AlphaSense, a leader in AI-powered market and enterprise intelligence,...

AWS Opens Innovation Hub to Boost Cloud & AI in APAC

Amazon Web Services (AWS), an Amazon.com company, has officially...

Wunderkind Unveils Build: A Dev-Ready Marketing Framework

Wunderkind, the agentic AI decisioning platform known for delivering...
spot_imgspot_img

Biodesix, Inc., a leading diagnostic solutions company with a focus in lung diseases, announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer.

Biodesix will utilize its array of genomics, proteomics, and data mining capabilities with the aim of developing and commercializing oncology biomarker assays in collaboration with MSK. Bio-Rad will provide its industry-leading digital PCR assay technology in support of this important work.

Also Read: Lumanity and Sorcero Announce Partnership to Deliver AI-Powered Medical Strategy and Communications

“The expansion of our previous master sponsored research agreement (MSRA) into a master collaborative research agreement with MSK is a significant milestone for Biodesix and for biomarkers in oncology diagnostics. Biodesix looks forward to co-developing and validating new test concepts under these agreements,” said Scott Hutton, CEO, Biodesix.

“We look forward to working with Biodesix to develop the next generation of highly multiplexed digital PCR assays as part of our expanding oncology offering,” said Simon May, EVP and President of Life Sciences at Bio-Rad Laboratories. “Bio-Rad provides the leading solution for digital PCR, and we are committed to providing oncology researchers and commercial partners with technologies that enable everything from biomarker discovery to clinical trials and patient monitoring of minimal residual disease.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img